SCHEMBL22061574

SCHEMBL22061574

Cc1cccc(Sc2cc(Sc3cccc(C)n3)cc(Sc3cccc(C)n3)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
CCR1 P32246 1/20 0.44
CCR8 P51685 1/20 0.44
GRM5 P41594 5/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NOTUM Q6P988 1/20 0.42
NOS3 P29474 1/20 0.41
NOS2 P35228 1/20 0.41
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
ESR1 P03372 1/20 0.35
AR P10275 1/20 0.35
HSD17B3 P37058 1/20 0.35
RAB9A P51151 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11730085 0.81 CCR1 (0.52) MAPTLMNAHTTCCR1CCR8
SCHEMBL10647459 0.80 NR1H2 (0.46) MAPTLMNAHTTCCR1CCR8
SCHEMBL2964870 0.77
SCHEMBL25256773 0.75 ALDH1A1 (0.42) MAPTLMNAHTTGRM5RAB9A
SCHEMBL22561744 0.73
SCHEMBL25219245 0.71 KDM4E (0.48) MAPTLMNAHTTMEN1KMT2A
SCHEMBL11728692 0.71 CCR1 (0.46) MAPTLMNAHTTCCR1CCR8
SCHEMBL10647452 0.71 LMNA (0.44) MAPTLMNAHTTCCR1CCR8
SCHEMBL27529897 0.71 NOTUM (0.47) MAPTLMNAHTTCCR1CCR8
SCHEMBL2616100 0.70 CCR1 (0.44) MAPTLMNAHTTCCR1CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4212513-A1 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE DERIVATIVES AND RELATED COMPOUNDS AS NLRX1 LIGANDS FOR TREATING INFLAMMATORY DISEASES LANDOS BIOPHARMA, INC. (US) 2023-07-19 EP disclosed
US-20210309610-A1 NLRX1 LIGANDS LANDOS BIOPHARMA, INC. (US) 2021-10-07 US disclosed
US-11066364-B2 NLRX1 ligands LANDOS BIOPHARMA, INC. (US) 2021-07-20 US disclosed
US-20200255378-A1 NLRX1 LIGANDS LANDOS BIOPHARMA, INC. (US) 2020-08-13 US disclosed
US-10676436-B2 NLRX1 ligands LANDOS BIOPHARMA, INC. (US) 2020-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309610-A1 NLRX1 LIGANDS NLRP1, NLRP3, NOD1 MAPT 2336/4885LMNA 3512/4885HTT 2535/4885
US-20200255378-A1 NLRX1 LIGANDS NLRP1, NLRP3, NOD1 MAPT 2336/4885LMNA 3512/4885HTT 2535/4885
US-11066364-B2 NLRX1 ligands NLRP1, NLRP3, NOD1 MAPT 2336/4885LMNA 3512/4885HTT 2535/4885
US-10676436-B2 NLRX1 ligands NLRP1, NLRP3, NOD1 MAPT 2336/4885LMNA 3512/4885HTT 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.